ArticleDiscover oncology2025
Prognostic and immunological profiling of SEC61G in cervical squamous cell carcinoma and adenocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Advances in SEC61G research: from ER translocon subunit to emerging pan-cancer oncogenic roles.Cancer biology & therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCervical squamous cell carcinoma and adenocarcinoma are major challenges to women's health worldwide, with incidence and mortality rates ranking first among female reproductive tract malignancies in China. The correlation between the SEC61G gene and cervical squamous cell carcinoma and adenocarcinoma remains unclear. In this study, we aimed to demonstrate the prognostic value and potential biological function of SEC61G in these cancers.
methodsThis study obtained pan-cancer and cervical squamous cell carcinoma and adenocarcinoma data from UCSC XENA. Cox regression analysis and Kaplan-Meier survival analysis were used to evaluate the prognostic value of SEC61G in pan-cancer and cervical cancers. TIMER and CIBERSORT were used to assess the relationship between SEC61G expression and immune cell populations.
resultsElevated expression of SEC61G was observed in various malignancies. Kaplan-Meier survival analysis demonstrated a significant association between SEC61G expression and overall survival (OS) in multiple cancers, including cervical squamous cell carcinoma and adenocarcinoma. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that SEC61G has substantial diagnostic utility for cervical cancers as well as other malignancies. Additionally, correlation analyses revealed a significant relationship between SEC61G expression and immune cell populations.
conclusionThis study provides the first comprehensive analysis of the role of SEC61G in pan-cancer and cervical squamous cell carcinoma and adenocarcinoma. Our findings suggest that SEC61G can serve as a diagnostic biomarker and prognostic indicator for cervical cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.